Nurtec® ODT (rimegepant) orally disintegrating tablets, 75mg 8-Unit Do

Published by Reclia Safety Desk | July 19, 2026

Recall Information Record
Reclia – Consumer Safety Database

1. Recall Summary
On March 16, 2023, Pfizer Inc., in cooperation with Biohaven Pharmaceuticals Inc., initiated a recall of Nurtec ODT (rimegepant) 75 mg orally disintegrating tablets. The recall was issued because the product’s packaging fails to meet the child-resistant packaging requirements mandated by the Poison Prevention Packaging Act (PPPA). The recall notice was published by the U.S. Consumer Product Safety Commission (CPSC) under Recall Number 23154. Approximately 4.2 million units are affected. No injuries have been reported in connection with this recall.

2. Affected Products
The recalled product is Nurtec® ODT (rimegepant) 75 mg orally disintegrating tablets, sold in cartons containing one blister card of 8 tablets. The tablets are packaged in a non-child-resistant blister card, which is placed inside a carton that displays the product name, dosage strength, and expiration date. The dosage strength and expiration date are also printed or stamped directly on the blister card.

– Product Description: Nurtec® ODT (rimegepant) 75 mg 8-Unit Dose blister pack
– NDC Number: 72618-3000-2
– Expiration Dates: All dates through June 2026
– Number of Units: Approximately 4.2 million
– Distribution: Sold by pharmacies nationwide as a prescribed medicine from December 2021 through March 2023. Prices varied based on health insurance terms and other factors.
– Manufacturer: Biohaven Pharmaceuticals Inc., of New Haven, Conn., and Pfizer Inc., of New York.
– Country of Manufacture: United States

3. Hazard Information
The recalled prescription drugs are required by the Poison Prevention Packaging Act (PPPA) to be in child-resistant packaging. The packaging of the affected products is not child resistant. This poses a risk of poisoning if the contents are swallowed by young children. As of the recall publication date, no injuries have been reported.

4. Consumer Action Required
Consumers who have the recalled product should take the following actions immediately, as stated in the recall notice:
– Immediately secure the recalled product out of the sight and reach of children.
– Contact Pfizer to request a free child-resistant pouch to store the product.
– Once the product is secured in the child-resistant pouch, consumers can continue to use the medication as directed by their healthcare provider.

5. Official Remedy
The official remedy offered by Pfizer is the provision of a free child-resistant pouch to consumers. This pouch is intended to be used for storing the recalled medication to mitigate the risk of accidental ingestion by children. The remedy is classified as “New Instructions” and “Repair” in the recall notice. No refund, replacement product, or other remedy is specified in the source data.

6. Contact Information
Consumers may contact Pfizer for more information or to request a free child-resistant pouch using the following methods:
– Phone: 800-879-3477, Monday through Friday, 9 a.m. to 7 p.m. ET
– Online: www.pfizer.com/contact
– Product Website: www.Nurtec.com/PackagingUpdate, or visit www.Nurtec.com and click the link titled “Recall to provide child resistant pouches to patients for storage of their medicine. Click for details” for more information.

Note: This record is based solely on the information provided in the CPSC recall notice. Any details not present in the source data are marked as “Not specified in the recall notice.” No testing, safety analysis, or editorial judgment has been applied by Reclia.

Frequently Asked Questions